Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27656222 | 0.87 | LMNA (0.56) | LMNAGAANPC1RAB9ACYP2C9 | |
| SCHEMBL30102436 | 0.85 | LMNA (0.55) | LMNAGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL148900 | 0.85 | LMNA (0.55) | LMNAGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3550940 | 0.84 | LMNA (0.54) | LMNAGAANPC1RAB9A | |
| SCHEMBL30572236 | 0.84 | LMNA (0.54) | LMNAGAANPC1RAB9A | |
| SCHEMBL192851 | 0.84 | LMNA (0.54) | LMNAGAANPC1RAB9ACYP2C9 | |
| SCHEMBL4188205 | 0.83 | LMNA (0.46) | LMNAGAANPC1RAB9A | |
| SCHEMBL4195184 | 0.81 | LMNA (0.55) | LMNAGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6124687 | 0.81 | LMNA (0.62) | LMNAGAANPC1RAB9ACYP2C9 | |
| SCHEMBL19616100 | 0.80 | TUBB4A (0.41) | LMNAGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824828-A2 | PYRIDINE BASED COMPOUNDS USEFUL AS INTERMEDIATES FOR PHARMACEUTICAL OR AGRICULTURAL END-PRODUCTS | Peakdale Molecular Limited (GB) | 2007-08-29 | — | — | EP | claimed |
| WO-2006059103-A2 | PYRIDINE BASED COMPOUNDS USEFUL AS INTERMEDIATES FOR PHARMACEUTICAL OR AGRICULTURAL END-PRODUCTS | PEAKDALE MOLECULAR LIMITED (GB) | 2006-06-08 | — | — | WO | claimed |
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
| WO-2012068210-A1 | PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-24 | — | — | WO | disclosed |
| US-20120129843-A1 | PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PEAKDALE MOLECULAR LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PEAKDALE MOLECULAR LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PEAKDALE MOLECULAR LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-1824828-A2 | PYRIDINE BASED COMPOUNDS USEFUL AS INTERMEDIATES FOR PHARMACEUTICAL OR AGRICULTURAL END-PRODUCTS | Peakdale Molecular Limited (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006059103-A2 | PYRIDINE BASED COMPOUNDS USEFUL AS INTERMEDIATES FOR PHARMACEUTICAL OR AGRICULTURAL END-PRODUCTS | PEAKDALE MOLECULAR LIMITED (GB) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129843-A1 | PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP1, MMP9, TIMP3 | LMNA 752/4885GAA 2667/4885NPC1 4846/4885 |
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | LMNA 4030/4885GAA 1394/4885NPC1 1495/4885 |
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1S, KCNN4 | LMNA 2098/4885GAA 1830/4885NPC1 762/4885 |
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PNPO, CYP4B1, PDXK | LMNA 3915/4885GAA 875/4885NPC1 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.